Joe Wiley

Operates as a biopharmaceutical company that develops and commercializes therapies for hyperlipidemia and metabolic diseases

Sofinnova Investment invests in companies located in the United States and Europe. The firm targets companies operating in the fields of health technology services and life science. It participates in early and later stage capital requirements.

AAMPE is an active investor supported by the group's fundamental bottom-up research and process-driven approach. Their objective is to add value. They target UK mid-market investments ranging from GBP 10 million and GBP 50 million with a particular focus on support services, consumer and leisure, specialist manufacturing and financial services. They also have a particular interest in the environmental sector and in business services. AAMPE's key investment selection criteria within their targeted sectors are the prospective firms' management and business model and attractively priced opportunities. They eschew benchmarks and follow a team-based approach for all investment decisions.

Functions as a College/University

Inventages Venture invests in companies located across the globe. The firm targets companies operating in the fields of diagnostics, drugs, OTC, medical and functional foods, nutraceuticals and enabling technologies. It provides financing for seed and early stage capital requirements.

Engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases

Synova Capital invests in lower mid-market companies located in the United Kingdom, Ireland and continental Europe. with an enterprise value of EUR 20 - 250 million. The firm targets companies operating in the fields of software & data, tech enabled services and financial services sectors. It provides financing for buy-ins, buy-outs and development capital transactions with an investment size of EUR 15 - 150 million.

Wholesales medical products